Erschienen in:
01.07.2024 | Research Letter
Metabolic effects of upadacitinib in patients with psoriasis and atopic dermatitis
verfasst von:
Marielos I. Posada Posada, Maria Beatrice Alora, Xinaida Taligare Vasconcelos Lima
Erschienen in:
Archives of Dermatological Research
|
Ausgabe 5/2024
Einloggen, um Zugang zu erhalten
Excerpt
Upadacitinib, a selective JAK-1 inhibitor, is FDA-approved for treating psoriatic arthritis (PsA) and atopic dermatitis (AD) [
1‐
3]. Although found to be effective and safe in clinical trials, it has been associated with metabolic abnormalities [
4,
5]. We aimed to evaluate the metabolic effects of upadacitinib in psoriasis (PsO) and AD patients in a real-world scenario. …